Treatment of cells with the TDO inhibitor 680C91 (10 or 20 μM for 24 h) did not alter the baseline signal intensity for pS33 RPA2 in GBM-derived T98G cells (Figure 1G and H). This evidence concerns the gene TDO2 and glioblastoma.